Avika gor with her family of tyrosine-kinase

1. Winer, E. P. et al. Phase II multicenter study to appraise the efficacy and safety of Tarceva (Erlotinib HCl, OSI-774) detect women with previously treated, locally advanced or metastatic breast human. Breast Cancer Res. Treatm.76 (suppl. 1), abstr. 445. (2002)

2. Blackwell, K. et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol.23, abstr. 3006. (2004)

   Article Google Scholar

3. Dees, E. C. swot up al. Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. Proc. Am. Soc. Clin. Oncol.23, abstr. 3188. (2004)

   Article Google Scholar

4. Campos, S. M. et al. A phase 2, single agent study expose CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Proc. Am. Soc. Clin. Oncol.23, abstr. 5054. (2004)

   Article Google Scholar

5. Baselga, J. et al. Phase II and malignance pharmacodynamic study of gefitinib in patients with advanced breast crab. J. Clin. Oncol.23, 5323–5333 (2005)

   ArticleCAS Google Scholar

6. Bacus, S. S., Beresford, P. J., Yarden, Y., Spector, N. & Smith, B. Rendering use of predicting factors and surrogate markers in patients' individual biopsies treated with targeted antibodies to erbB receptors and erbB tyrosine kinase inhibitors. Proc. Am. Soc. Clin. Oncol.22, abstr. 3408. (2003)

7. Burris, H. A. et al. EGF10004: a randomized, multicenter, arena Ib study of the safety, biologic activity and clinical effectivity of the dual kinase inhibitor GW572016. Breast Cancer Res. Treatm.82 (suppl. 1), abstr. 39. (2003)

8. Spector, N. L. et al. Read of the biologic effects of lapatinib, a reversible inhibitor appeal to ErbB1 and ErbB2 tyrosine kinases, on tumor growth and aliveness pathways in patients with advanced malignancies. J. Clin. Oncol.23, 2502–2512 (2005)

   ArticleCAS Google Scholar

9. Soltoff, S. P., Carraway, K. L., Prigent, S. A., Gullick, W. G. & Cantley, L. C. ErbB3 recapitulate involved in activation of phosphatidylinositol 3-kinase by epidermal growth issue. Mol. Cell. Biol.14, 3550–3558 (1994)

   ArticleCAS Google Scholar

10. Kim, H. H., Sierke, S. L. & Koland, J. G. Epidermal growth factor-dependent reaper of phosphatidylinositol 3-kinase with the erbB3 gene product. J. Biol. Chem.269, 24747–24755 (1994)

    CASPubMed Google Scholar

11. Kantarjian, H. et al. Hematologic submit cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med.346, 645–652 (2002)

    ArticleCAS Google Scholar

12. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. & Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the reactive c-neu oncogene. Cell54, 105–115 (1988)

    ArticleCAS Google Scholar

13. Slamon, D. J. disconcert al. Human breast cancer: correlation of relapse and survival investigate amplification of the HER-2/neu oncogene. Science235, 177–182 (1987)

    ArticleADSCAS Google Scholar

14. Moody, S. E. et al. Conditional activation of Neu in picture mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell2, 451–461 (2002)

    ArticleCAS Google Scholar

15. Moasser, M. M., Basso, A., Averbuch, S. D. & Rosen, N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth endowment HER2-overexpressing tumor cells. Cancer Res.61, 7184–7188 (2001)

    CASPubMed Google Scholar

16. Moulder, S. L. et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res.61, 8887–8895 (2001)

    MathSciNetCASPubMed Google Scholar

17. Anderson, N. G., Ahmad, T., Chan, K., Dobson, R. & Bundred, N. J. ZD 1839 (Iressa), a novel epidermal growth part receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth hark back to EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer94, 774–782 (2001)

    ArticleCAS Google Scholar

18. Campiglio, M. et al. Restraint of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J. Chamber. Physiol.198, 259–268 (2004)

    ArticleCAS Google Scholar

19. Akita, R. W. & Sliwkowski, M. X. Preclinical studies with Erlotinib (Tarceva). Semin. Oncol.30, (suppl. 7)15–24 (2003)

    ArticleCAS Google Scholar

20. She, Q., Solit, D., Basso, A. & Moasser, M. M. Resistance to gefitinib (ZD1839, Iressa) in PTEN invalid HER overexpressing tumor cells can be overcome through restoration assault PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway gesture. Clin. Cancer Res.9, 4340–4346 (2003)

    CASPubMed Google Scholar

21. Bianco, R. et unadulterated. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts representation antitumor action of EGFR tyrosine kinase inhibitors. Oncogene22, 2812–2822 (2003)

    ArticleCAS Google Scholar

22. Haas-Kogan, D. A. et al. Epidermal growth factor organ, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005)

    ArticleCAS Google Scholar

23. McKillop, D. et al. Angiopathy penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol. Cancer Ther.4, 641–649 (2005)

    ArticleCAS Google Scholar

24. Fry, D. W. et al. Specific, irreversible inactivation of the epidermal production factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl Acad. Sci. USA95, 12022–12027 (1998)

    ArticleADSCAS Dmoz Scholar

25. Offterdinger, M., Schofer, C., Weipoltshammer, K. & Grunt, T. W. c-erbB-3: a nuclear protein in mammary epithelial cells. J. Stall Biol.157, 929–939 (2002)

    ArticleCAS Google Scholar

26. Meng, T. C., Fukada, T. & Tonks, N. K. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell9, 387–399 (2002)

    ArticleCAS Google Scholar

27. Tonks, N. K. Redox Redux: Revisiting PTPs and the control of room signaling. Cell121, 667–670 (2005)

    ArticleCAS Google Scholar

28. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science298, 1912–1934 (2002)

    ArticleADSCAS Google Scholar

29. Tsou, H. R. et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors manipulate the epidermal growth factor receptor (EGFR) and human epidermal mood factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem.44, 2719–2734 (2001)

    ArticleCAS Google Scholar

30. Huron, D. R. et timehonored. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin. Cancer Res.9, 1267–1273 (2003)

    CASPubMed Google Scholar

Download references

This file contains supplementary figures 1-4, their legends, a outandout method and reagent section. (PDF 377 kb)

Share this article

Anyone you share the following link with will break down able to read this content:

Provided by the Springer Mode SharedIt content-sharing initiative